$CELC News

Craig-Hallum Maintains Buy on Celcuity, Lowers Price Target to $171

Wells Fargo Maintains Overweight on Celcuity, Lowers Price Target to $166

Celcuity: Selloff On Yesterday's Data Unwarranted; Buy Rating Upheld

HC Wainwright & Co. Maintains Buy on Celcuity, Lowers Price Target to $145

Celcuity Announces Proposed Underwritten Public Offering Of $400M Aggregate Principal Amount Of Convertible Senior Notes Due 2032

Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib Efficacy Transcript

What's Going On With Celcuity Stock On Tuesday?

Celcuity Announces Efficacy And Safety Results From The PIK3CA Mutant Cohort Of Its Phase 3 VIKTORIA-1 Clinical Trial Of Gedatolisib, With 50% Reduced Risk Of Disease Progression Or Death

Celcuity To Host Conference Call And Live Webcast To Review Results From PIK3CA Mutant Cohort Of Phase 3 VIKTORIA-1 Clinical Trial On June 2

Celcuity To Host Conference Call And Live Webcast To Review Results From PIK3CA Mutant Cohort Of Phase 3 VIKTORIA-1 Clinical Trial On June 2

HC Wainwright & Co. Maintains Buy on Celcuity, Raises Price Target to $185

Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst

Wells Fargo Maintains Overweight on Celcuity, Raises Price Target to $183

Needham Reiterates Buy on Celcuity, Maintains $157 Price Target

Celcuity Inc. (NASDAQ:CELC) Q1 Earnings Beat Forecasts, But Stock Drops on Phase 3 Data Focus

Celcuity Inc. (CELC) Q1 2026 Earnings Call Transcript

Transcript: Celcuity Q1 2026 Earnings Conference Call

Celcuity Q1 Adj. EPS $(0.86) Beats $(1.05) Estimate

Celcuity Expands Phase 3 VIKTORIA-2 Clinical Trial Of Gedatolisib As A First-line Treatment

Citizens Maintains Market Outperform on Celcuity, Raises Price Target to $160